Please login to the form below
everolimus
This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
Pfizer and Arvinas are also planning to initiate two additional trials of ARV-471 this year, including a second phase 1b combination trial with cancer growth blocker everolimus, as well as
Latest news
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients.
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In addition to the positive results for the Keytruda plus Lenvima combination, Merck and Eisai added that Lenvima plus everolimus also showed improvements in PFS and ORR compared to Sutent. ... However, Lenvima plus everolimus did not demonstrate an
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
In a separate arm of the KEYNOTE-581 trial, the partner companies also evaluated Lenvima plus Novartis’ Afinitor (everolimus) in advanced RCC, with this combination also topping Sutent on PFS and
-
BMS unveils long-term results for Opdivo in kidney cancer
alive at this time-point compared to 18% of those treated only with the standard chemotherapy drug everolimus.
-
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is
More from news
Approximately 8 fully matching, plus 68 partially matching documents found.
Latest from PMHub
-
Oncology drugs under AMNOG
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
